Dan Lü

3.7k citations

67 papers · 2.4k indexed · 1 hit paper · h-index 25

Impact in

Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment

Papers in ⓘ

Oncology 26
- HER2/EGFR in Cancer Research 11
- CAR-T cell therapy research 10
Immunology 20
- Immune Cell Function and Interaction 11
- T-cell and B-cell Immunology 8
- Immunotherapy and Immune Responses 6

Co-authors: Peter Böhlen (5 shared papers)Ie Ming Shih (2 shared papers)Morgan A. Marks (1 shared paper)Anna Yemelyanova (1 shared paper)Russell Vang (1 shared paper)Robert J. Kurman (1 shared paper)Malti Kshirsagar (1 shared paper)Zhenping Zhu (5 shared papers)
Journals: CPT Pharmacometrics & Systems Pharmacology (5 papers)Frontiers in Immunology (4 papers)Cancer Research (4 papers)Blood (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)
Partner nations: United States China France

In The Last Decade

Dan Lü

66 papers receiving 2.3k citations

Hit Papers

align trajectories log scale

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis 2011 · 386 citations

Peers

Countries citing papers authored by Dan Lü

Since Specialization

Citations

This map shows the geographic impact of Dan Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Lü more than expected).

Fields of papers citing papers by Dan Lü

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Lü. The network helps show where Dan Lü may publish in the future.

Co-authors

The 25 scholars most cited alongside Dan Lü, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dan Lü Line = papers co-authored together Dan Lü links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis Modern Pathology ·Anna Yemelyanova, Russell Vang, Malti Kshirsagar, Dan Lü, Morgan A. Marks, Ie Ming Shih, Robert J. Kurman Hit paper breakdown →	2011	386
2	Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin Nature ·Chester Lee Drum, Shui-Zhong Yan, Joel Bard, Yuequan Shen, Dan Lü, Sandriyana Soelaiman, Zenon Grabarek, Andrew Bohm, Wei‐Jen Tang	2002	317
3	Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity Journal of Biological Chemistry ·Dan Lü, Juqun Shen, Marie Danielle Vil, Haifan Zhang, Xenia Jimenez, Peter Böhlen, Larry Witte, Zhenping Zhu	2003	156
4	Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity Leukemia ·Z Zhu, Koichi Hattori, H Zhang, Xenia Jimenez, Dale L. Ludwig, Sérgio Dias, Paul Kussie, Henry Koo, H J Kim, Dan Lü, Meilin Liu, Rafael Enrique Tejada, M Friedrich, Peter Böhlen, Luc de Witte, Shahin Rafii	2003	131
5	Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy International Journal of Cancer ·Dan Lü, Xenia Jimenez, Haifan Zhang, Peter Böhlen, Larry Witte, Zhenping Zhu	2001	122
6	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study The Lancet Oncology ·Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, Amitkumar Mehta, Gilles Salles, Corinne Haïoun, Javier Muñoz, Andy I. Chen, Kathryn S. Kolibaba, Dan Lü, Mark Yan, Elicia Penuel, Jamie Hirata, Calvin Lee, Jeff P. Sharman	2019	93
7	Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion Cancer Research ·Ken-Yu Lin, Dan Lü, Chien‐Fu Hung, Shiwen Peng, Lanqing Huang, Chunfa Jie, F. Murillo, Jesse W. Rowley, Ya-Chea Tsai, Liangmei He, Dae‐Jin Kim, Elizabeth M. Jaffee, Drew M. Pardoll, T.‐C. Wu	2007	71
8	Evaluating the impact of land fragmentation on the cost of agricultural operation in the southwest mountainous areas of China Land Use Policy ·Yahui Wang, Xiubin Li, Dan Lü, Jianzhong Yan	2020	70
9	Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark W. Brunvand, André Goy, Elizabeth Chang, Ephraim P. Hochberg, Sreeni Yalamanchili, Robert S. Kahn, Dan Lü, Priya Agarwal, Randall Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Waye Chu, Bruce D. Cheson	2016	65
10	Biochemical Association of CD45 with the T Cell Receptor Complex Immunity ·David Leitenberg, Yvan Boutin, Dan Lü, Kim Bottomly	1999	61
11	Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies Journal of Biological Chemistry ·Dan Lü, Paul Kussie, Bronislaw Pytowski, Kris Persaud, Peter Böhlen, Larry Witte, Zhenping Zhu	2000	59
12	Comparison of candidate serologic markers for type I and type II ovarian cancer Gynecologic Oncology ·Dan Lü, Elisabetta Kuhn, Robert E. Bristow, Robert Giuntoli, Susanne K. Kjær, Ie‐Ming Shih, Richard B.S. Roden	2011	45
13	Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways Vascular Pharmacology ·Rong Pan, Yue Dai, Xinghua Gao, Dan Lü, Yufeng Xia	2010	44
14	A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities Cancer Chemotherapy and Pharmacology ·Dan Lü, Tong Lu, Mark Stroh, Richard Graham, Priya Agarwal, Luna Musib, Chi‐Chung Li, Bert L. Lum, Amita Joshi	2016	41
15	Modeling Spatiotemporal Population Changes by Integrating DMSP-OLS and NPP-VIIRS Nighttime Light Data in Chongqing, China Remote Sensing ·Dan Lü, Yahui Wang, Qingyuan Yang, Kangchuan Su, Haozhe Zhang, Yuanqing Li	2021	40
16	(±)-Praeruptorin A enantiomers exert distinct relaxant effects on isolated rat aorta rings dependent on endothelium and nitric oxide synthesis Chemico-Biological Interactions ·Xu Zhao, Xiaobing Wang, Yue Dai, Ling‐Yi Kong, Fengyun Wang, Huan Xu, Dan Lü, Jie Song, Zhiguo Hou	2010	39
17	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy Frontiers in Immunology ·Dan Lü, Zepeng Xu, Ding Zhang, Min Jiang, Kefang Liu, Juanhua He, Dongli Ma, Xiaopeng Ma, Shuguang Tan, George F. Gao, Yan Chai	2022	35
18	p53 autoantibodies, cytokine levels and ovarian carcinogenesis Gynecologic Oncology ·Miyun Tsai-Turton, Antonio Santillan, Dan Lü, Robert E. Bristow, Kwun Chuen Gary Chan, Ie Ming Shih, Richard B.S. Roden	2009	32
19	Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens CPT Pharmacometrics & Systems Pharmacology ·Dan Lü, WR Gillespie, Sandhya Girish, Priya Agarwal, C Li, Jamie Hirata, Y‐W Chu, Matts Kågedal, (unknown), Vidya Maiya, JY Jin	2017	32
20	Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma CPT Pharmacometrics & Systems Pharmacology ·Dan Lü, Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Priya Agarwal, Colby S. Shemesh, Rong Shi, Randall Dere, Jamie Hirata, Dale Miles, Pascal Chanu, Sandhya Girish, Jin Y. Jin	2019	30

About Dan Lü

Dan Lü is a scholar working on Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Molecular Biology, having authored 67 papers that have together received 2.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers), HER2/EGFR in Cancer Research (11 papers), Immune Cell Function and Interaction (11 papers), CAR-T cell therapy research (10 papers), T-cell and B-cell Immunology (8 papers), Immunotherapy and Immune Responses (6 papers) and Glycosylation and Glycoproteins Research (6 papers). The work is most often cited by research in Oncology (856 citations), Reproductive Medicine (160 citations), Immunology (388 citations), Cancer Research (271 citations) and Pathology and Forensic Medicine (321 citations). Dan Lü has collaborated with scholars based in United States, China and France. Frequent co-authors include Peter Böhlen, Ie Ming Shih, Morgan A. Marks, Anna Yemelyanova, Russell Vang, Robert J. Kurman, Malti Kshirsagar, Zhenping Zhu, Larry Witte and Xenia Jimenez. Their work appears in journals such as CPT Pharmacometrics & Systems Pharmacology, Frontiers in Immunology, Cancer Research, Blood and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact